Bioequivalence Final Rule Requires “Appropriate” Sampling For ANDA Tests
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule on bioavailability and bioequivalence for ANDAs requires "appropriate" sampling to establish a drug's steady state instead of sampling on three consecutive days as outlined in the proposed rule